AstraZeneca(US:AZN) Nan Fang Du Shi Bao·2025-11-10 13:34Group 1 - AstraZeneca showcased a strong commitment to innovation and sustainable development at the China International Import Expo, with a 1,000 square meter booth and over 30 events [2] - The company announced an additional investment of approximately $136 million in a Qingdao inhalation aerosol production project to meet clinical needs for asthma and COPD patients, reflecting its deepening engagement in the Chinese market [4] - AstraZeneca has cumulatively invested over $1.8 billion in China, with the opening of its second strategic R&D center in Beijing, which is part of a $2.5 billion investment plan [4] Group 2 - The company displayed over 40 innovative drugs and plans to accelerate the introduction of new drugs in chronic diseases, oncology, and rare diseases over the next two years [6] - AstraZeneca hosted over 30 events during the expo, including the launch of the "Health Day" series and patient care forums, focusing on innovative treatment pathways and payment models in various therapeutic areas [6] - The company emphasizes sustainable development across its entire value chain, with significant achievements in its production bases in Wuxi, Taizhou, and Qingdao, including a 100% renewable energy usage in Wuxi and a 97.5% reduction in carbon emissions at the Taizhou base compared to 2015 [8] Group 3 - AstraZeneca is committed to contributing to the "Healthy China 2030" goal by collaborating with various stakeholders to promote high-quality development in the Chinese healthcare industry [8]